<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01054300</url>
  </required_header>
  <id_info>
    <org_study_id>8835-040</org_study_id>
    <nct_id>NCT01054300</nct_id>
  </id_info>
  <brief_title>Effects Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Single Day Evaluation Of The Pharmacokinetic-Pharmacodynamic Effect Of Once And Twice Daily Oral Administration Of PF-04971729 In Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 pharmacokinetic, pharmacodynamic study to understand the manner in which
      the body responds to, as well as how the drug is handled by the body, with once vs twice
      daily dosing of ertugliflozin (PF-04971729, MK-8835) in participants with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour mean urinary glucose excretion</measure>
    <time_frame>Up to 24 hours in each dosing period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time course of the urinary glucose excretion</measure>
    <time_frame>Up to 24 hours in each dosing period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>24-hour weighted mean plasma glucose.</measure>
    <time_frame>Up to 24 hours in each dosing period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Weighted mean postprandial plasma glucose</measure>
    <time_frame>Up to 24 hours in each dosing period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting plasma glucose</measure>
    <time_frame>Up to 24 hours in each dosing period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting C-peptide</measure>
    <time_frame>Up to 24 hours in each dosing period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event (AE)</measure>
    <time_frame>Up to Day 7 in each dosing period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinuing Study Drug Due to an AE</measure>
    <time_frame>Up to Day 1 in each dosing period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) from time 0 to time of the last quantifiable concentration (AUClast) for ertugliflozin</measure>
    <time_frame>Up to 24 hours in each dosing period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of ertugliflozin</measure>
    <time_frame>Up to 24 hours in each dosing period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time taken to reach the maximum observed plasma concentration (Tmax) of ertugliflozin</measure>
    <time_frame>Up to 24 hours in each dosing period</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Adult</condition>
  <arm_group>
    <arm_group_label>Ertugliflozin (E) 2 mg/Placebo (P)→E 1 mg/E 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 (AM/PM) dose: E 2 mg/Placebo. Period 2 (AM/PM) dose: E 1 mg /E 1 mg. There was a &gt;= 7 day washout period between Period 1 and Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E 1 mg/E 1 mg→E 2 mg/P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 (AM/PM) dose: E 1 mg/E 1 mg. Period 2 (AM/PM) dose: E 2 mg /Placebo. There was a &gt;= 7 day washout period between Period 1 and Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E 4 mg/P→E 2 mg/E 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 (AM/PM) dose: E 4 mg/Placebo. Period 2 (AM/PM) dose: E 2 mg /E 2 mg. There was a &gt;= 7 day washout period between Period 1 and Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E 2 mg/E 2 mg→E 4 mg/P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 (AM/PM) dose: E 2 mg/E 2 mg. Period 2 (AM/PM) dose: E 4 mg /Placebo. There was a &gt;= 7 day washout period between Period 1 and Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 2 mg single dose</intervention_name>
    <description>Ertugliflozin 2 mg dose (using 1 mg strength tablets), administered as a single dose</description>
    <arm_group_label>Ertugliflozin (E) 2 mg/Placebo (P)→E 1 mg/E 1 mg</arm_group_label>
    <arm_group_label>E 1 mg/E 1 mg→E 2 mg/P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 2 mg split into twice daily</intervention_name>
    <description>Ertugliflozin 1 mg dose (using 1 mg strength tablets) administered twice daily x 1 day</description>
    <arm_group_label>Ertugliflozin (E) 2 mg/Placebo (P)→E 1 mg/E 1 mg</arm_group_label>
    <arm_group_label>E 1 mg/E 1 mg→E 2 mg/P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 4 mg single dose</intervention_name>
    <description>Ertugliflozin 4 mg dose (using 1mg strength tablets), administered as a single dose</description>
    <arm_group_label>E 4 mg/P→E 2 mg/E 2 mg</arm_group_label>
    <arm_group_label>E 2 mg/E 2 mg→E 4 mg/P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 4 mg split into twice daily</intervention_name>
    <description>Ertugliflozin 2 mg dose (using 1 mg strength tablets) administered twice daily x 1 day</description>
    <arm_group_label>E 4 mg/P→E 2 mg/E 2 mg</arm_group_label>
    <arm_group_label>E 2 mg/E 2 mg→E 4 mg/P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to Ertugliflozin</description>
    <arm_group_label>Ertugliflozin (E) 2 mg/Placebo (P)→E 1 mg/E 1 mg</arm_group_label>
    <arm_group_label>E 1 mg/E 1 mg→E 2 mg/P</arm_group_label>
    <arm_group_label>E 4 mg/P→E 2 mg/E 2 mg</arm_group_label>
    <arm_group_label>E 2 mg/E 2 mg→E 4 mg/P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 2 diabetes, on up to 2 acceptable oral anti-diabetes drugs for at
             least 8-weeks prior to study.

        Exclusion Criteria:

          -  Patients with type 1 diabetes, patients with stroke, unstable angina, heart attack in
             last 6-months, uncontrolled blood pressure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2010</study_first_posted>
  <last_update_submitted>May 20, 2016</last_update_submitted>
  <last_update_submitted_qc>May 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>December 6, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

